Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038002 (
splenomegaly
)
9,873
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Pyran
copolymer (maleic anhydride-divinyl ether) has consistently reproducible molecular weight-related biologic effects associated with toxic, immunologic antitumor, and antiviral effects. Fortunately, the antitumor action occurs with the least toxic lower molecular weight fraction. Immunoadjuvant effects with this fraction would be critical to its development. Studies of polymers should include evaluation of effects on
splenomegaly
, splenic esterase changes, lipolysis, reverse transcriptase, nucleases, calcium flux, cyclic nucleotides, and complement and clotting elements.
...
PMID:Future direction of synthetic polyanions (pyran copolymer). 36 28
Treatment of mice with the immunomodulator pyran copolymer inhibited leukemogenesis produced by Friend leukemia virus (FLV) complex, as evidenced by inhibition of the spleen focus-forming virus and lymphatic leukemia virus, as well as by a significant decrease in
splenomegaly
. In this report we present data suggesting that the protective effect of pyran is mediated by macrophages. Protection was conferred on normal recipient mice when peritoneal exudate cells from pyran-treated mice were transferred to recipient mice infected 24 hr later with FLV. Animals receiving pyran-activated peritoneal cells had a significant reduction of
splenomegaly
and of titers of spleen focus-forming virus and lymphatic leukemia virus than did control animals. In contrast, when glycogen-elicited peritoneal exudate cells were transferred, the mice were not protected.
Pyran
-activated peritoneal cells, but not normal peritoneal cells, also inhibited FLV growth in vitro. Serum from pyran-treated, but not glycogen-treated, mice also transferred resistance to FLV-infected mice.
...
PMID:Cellular and serum involvement in protection against Friend leukemia virus. 90 40
Peritoneal macrophages from both congenitally athymic ("nude") mice and heterozygous littermates were activated by pyran copolymer or by Corynebacterium parvum vaccine. C parvum did not produce an increase in the number of peritoneal macrophages in nude mice, although it did produce a typical
splenomegaly
.
Pyran
produced an even greater influx of macrophages in the peritoneum of nude mice, when compared to normal mice, but did not produce
splenomegaly
in nude mice.
Pyran
- and C parvum-induced
splenomegaly
were accompanied by an increase in the apparent T-cell population of germinal centers. These experiments indicate that: 1) Macrophage activation, per se, by either C parvum, is a thymus-independent event; 2) Macrophage mobilization, as determined by organomegaly or PEC number, does not have an obligatory requirement for T-cells (depending on the agent used); 3) Macrophage activation may not always correlate with mobilization; and 4) Mechanisms for attracting and sequestering macrophages in the peritoneum may be different from those of the spleen.
...
PMID:Macrophage activation and mobilization in nude mice by Corynebacterium parvum and pyran: a functional and histologic study. 696 33